In an industry dominated by billion-dollar giants, Igenbio is playing a different game entirely. With just 4 employees and $600K in revenue, this biotech boutique is carving out a niche in genome sequencing that challenges the conventional wisdom of scale.

"They're not building the next Illumina—they're building the infrastructure that makes genomic data actually usable."

The leadership team tells the story. Vinayak Ph.D. as CEO, flanked by Benjamin Vaisvil and Daniel Schmitt—both bioinformatics software engineers. No MBA-heavy C-suite here. This is a technical-first organization where the founders are still in the trenches, building the product. That's rare and powerful in biotech, where companies often layer on management before finding product-market fit.

• The 'undefined' country in their traffic data suggests they're either pre-market fit or serving a global, distributed customer base that defies geographic clustering
• Their keyword strategy is defensive—they rank for their own branded terms and platform logins, not broad industry keywords
• The tech stack (Tailwind, Bootstrap, Ant Design) screams 'move fast and ship' rather than 'enterprise-grade security theater'